Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,337
datasets available to search
ShareScore release 0.9.0
Dataset results
1,337 results for “cervical cancer”
Supplementary files for Molecular Differences Between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers
<p>Supplementary files for Molecular Differences Between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers</p>
Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer
<p>This repository includes source data used to genrtate all tables and figures for published stduy "Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer". Besides, a small set of digital images for different class of cervical smear samples are included.</p>
Data to "Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer"
<p>This record includes the DICOM images and analysed data that were used in the multicenter QA program for quantitative MRI in cervical cancer as published (<a href="https://www.sciencedirect.com/science/article/pii/S0167814020307854?via%3Dihub">https://doi.org/10.1016/j.radonc.2020.09.013</a> ).</p> <p>The DICOM data includes the acquired DICOM data for each institute selected to those that were used in the publication. Acquisitions that were not used were removed. Data was anonymized with conquest dicom server tools.</p> <p>The analyzed data files are included giving per measurement the estimated quantitative parameter values as well as the position of the ROIs and extracted signal intensity values per phantom sample. An explanation of the structure of the files is added in the readme file. The analysis was done with in-house written code in matlab.</p> <p>Included are a description of the sequence parameters for each institute (IQEMBRACE_PhantomQA_OverviewInstitutionalSequenceParameters_20241114) and details on the choices in the analysis of the data (IQEMBRACE_PhantomQA_OverviewPhantomData_20241114). As background also the description of the measurements was added, giving more information on how the measurements were performed.</p> <p>This work was in preparation for the IQ-EMBRACE trial (clinicaltrials.gov NCT03210428)</p>
Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya
ClinicalTrials.gov study NCT03514459. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Cemiplimab in Adults With Cervical Cancer
ClinicalTrials.gov study NCT03257267. IPD Sharing: YES. Countries: 14. Publications: 2.
Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
ClinicalTrials.gov study NCT04679675. IPD Sharing: YES. Countries: 1. Publications: 2.
Cervical intraepithelial neoplasia acetic acid white images - pre-cancerous lesion three-class classification
Open the record for dataset details and reuse information.
Assessing Community Health Volunteers’ Knowledge Level on Cervical Cancer in Kadibo, Kisumu County: A Cross Sectional Survey-1
<p>Data set for the manuscript titled, "Assessing Community Health Volunteers’ Knowledge Level on Cervical Cancer in Kadibo, Kisumu County: A Cross Sectional Survey"</p>
Research data on health facility-level factors that contribute to delayed diagnosis of cervical cancer
<p>In Kenya, cervical cancer is the 2nd commonly diagnosed type of cancer and the top cause of cancer-related deaths among women. Globally, over 50% of cervical cancer diagnoses are made late, with this proportion rising to 80% in developing countries. Poor Health systems can cause delays in diagnosis, thus, this study focused on determining the health facility-level factors that contribute to delayed diagnosis among cervical cancer patients at the Kenyatta National Hospital (KNH). An analytical cross-sectional mixed method study was adopted to collect data on hospital and referral experiences from 139 cervical cancer patients systematically sampled at KNH, using a semi-structured questionnaire. Associations between the stage at diagnosis and hospital and referral experiences were tested using a logistic regression model at 95% Confidence Interval. 86 (61.9%) were diagnosed at advanced stages III and IV. The potential predictors for delayed diagnosis were; More number of hospital referral times (p-value=0.000), Facing referral challenges (p-value=0.041), Longer time taken for diagnosis appointment (p-value=0.059), and Longer time taken for diagnostic results (p-value=0.007) in the bivariate analysis. More number of hospital referral times (p-value=0.001) and longer time taken for diagnostic results (p-value=0.025), were significantly associated with delayed diagnosis of cervical cancer in the multivariate logistic regression test model. Referral challenges included misdiagnosis, cost of diagnosis, and prolonged diagnosis appointments. The study concluded that the cause of delays in diagnosis for most patients is due to poor health and referral systems and inadequate medical personnel and diagnosis equipment. This study recommends improving referral systems and encouraging partnerships to decentralize diagnostic centers and equipment and train more expertise on cervical cancer.</p>
Genomic signature for malignant tumour progression in cervical cancer
<p>To investigate the clinical genomic signatures associated with tumor progression, we performed genomic sequencing on patients with cervical cancer, including primary, recurrent, and metastatic tumor tissues, and obtained their somatic mutation and copy number alteration profiles.</p>
Accuracy of ultrasonography and magnetic resonance imaging for preoperative staging of cervical cancer – analysis of patients from the prospective study on total mesometrial resection.
<p>This is supplementary material to the manuscript published in the Diagnostics (MDPI) journal. </p> <p>Diagnostics 2021, 11, 1749</p> <p>https://doi.org/10.3390/diagnostics11101749</p> <p>Videos present examples of ultrasound examinations of patients with cervical cancer.</p>
Annona squamosa Leaf Extract Inhibit Migration of Human Cervical Cancer Cells Through MMP-9 Expression
<p> Figure 1. a.<em>Annona squamosa</em> leaf . b.Simplicia powder of <em>Annona squamosa</em> leaves</p> <p>Figure 2. <em>Annona squamosa</em> leaves ethanol extract.</p> <p>Figure 3. FTIR spectrophotometer results of acetogenin compounds of<em> </em><em>Annona squamosa</em> leaves extract</p> <p>Figure 4. The cytotoxic test of HeLa cells at 24 hours. The combination of ASL (<em>Annona squamosa</em> leaf Extract) 12.5 mg/ml + cisplatin was very effective compared with a single therapy. *<em>P</em> < 0.05Figure 4. The cytotoxic test of HeLa cells at 24 hours. The combination of ASL (<em>Annona squamosa</em> leaf Extract) 12.5 mg/ml + cisplatin was very effective compared with a single therapy. *<em>P</em> < 0.05</p> <p>Figure 5. The percentage of living cells of HeLa cells were cultured with different concentrations of <em>Annona squamosa</em> leaf extract.</p> <p>Figure 6. The combination therapy of ASL with cisplatin reduced the expressions of MMP-9 in HeLa cells. a. A significant concentration for cytotoxicity was a concentration of 12.5 mg/mL ASL + 5 μg/mL Cisplatin. b. The number of MMP-9 positive cells. *<em>P< </em>0.005.</p> <p>Figure 7. The combination therapy of ASL and Cisplatin inhibit cell migration. a. HeLa cells were treated with single cisplatin or in combination with ASL 12.5; 25, 50, and a single dose of ASL 75 mg/mL. b. Percentage area of cells undergoing migration. *<em>P</em><0.005.</p> <p> </p> <p> </p>
Supplementary Figure MiR-497-5p inhibits metastasis in cervical cancer
<p>Supplementary Figure A. Expression of apoptosis-related proteins, cleaved caspase 3 and cleaved caspase 9, was assayed by WB</p> <p>Supplementary Figure B. Cell migration and invasion abilities were assayed through transwell assay (Mann-Whitney test)</p> <p>Supplementary Figure C. Changes in expression of EMT-related proteins were assayed by WB (Mann-Whitney test). *<em>p</em><0.050 representing statistically significant.</p>
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
ClinicalTrials.gov study NCT00941070. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
ClinicalTrials.gov study NCT00128661. IPD Sharing: Not stated. Countries: 1. Publications: 26.
QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer
ClinicalTrials.gov study NCT07205497. IPD Sharing: YES. Countries: 1. Publications: 8.
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
ClinicalTrials.gov study NCT00101192. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
ClinicalTrials.gov study NCT00087126. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
ClinicalTrials.gov study NCT04910802. IPD Sharing: YES. Countries: 1. Publications: 1.
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ClinicalTrials.gov study NCT02466971. IPD Sharing: Not stated. Countries: 3. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.